Gaush Meditech Ltd. (2407) AI Stock Analysis

• Market Cap: HK$798.59M
• Dividend Yield: 3.48%
• Average Volume (3M): 147.22K
• Price to Earnings (P/E): 6.0
• Beta (1Y): 0.74
• Revenue Growth: 6.63%
• EPS Growth: 12.96%
• Country: HK
• Employees: 884
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.44
• Shares Outstanding: 147,887,860
• 10 Day Avg. Volume: 84,250
• 30 Day Avg. Volume: 147,220
• PEG Ratio: -0.32
• Price to Book (P/B): 0.87
• Price to Sales (P/S): 0.96
• P/FCF Ratio: 51.36
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 1.22
• Revenue Forecast (FY): HK$1.72B

• Rating: 74 Outperform
• Price Target: HK$7.50 ▼(-1.83% Downside)
• Action: N/A Date: 09/19/25
• Date: Action: N/A 09/19/25

Gaush Meditech Ltd. receives a solid score driven by strong technical indicators and a fair valuation. The financial performance is moderate, with stable revenue growth but challenges in profit margins and cash flow. The absence of recent earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Improved leverage

An improved debt-to-equity ratio (0.35) reduces financial leverage and interest burden, increasing balance sheet flexibility. That strengthens capacity to fund R&D, scale production or absorb shocks, lowering refinancing risk and supporting strategic moves over the next 2–6 months.

Negative Factors

Declining margins

Falling gross and net margins indicate pressure from higher input or operating costs or pricing stress. Sustained margin deterioration will erode earnings power and ROE, limit reinvestment capacity and require operational improvements or pricing adjustments to restore long-term profitability.

Gaush Meditech Ltd. Business Overview & Revenue Model

Company Description

Gaush Meditech Ltd., together with its subsidiaries, researches and develops, produces, and sells ophthalmic medical devices in the People's Republic of China and internationally. The company operates through Proprietary Products, Distribution, Te...

Read more

Gaush Meditech Ltd., together with its subsidiaries, researches and develops, produces, and sells ophthalmic medical devices in the People's Republic of China and internationally. The company operates through Proprietary Products, Distribution, Te...

How the Company Makes Money

Gaush Meditech generates revenue primarily through the sale of its medical devices and equipment to hospitals, clinics, and healthcare providers. The company employs a direct sales model complemented by partnerships with distributors to expand its...

Read more

Gaush Meditech generates revenue primarily through the sale of its medical devices and equipment to hospitals, clinics, and healthcare providers. The company employs a direct sales model complemented by partnerships with distributors to expand its...

Gaush Meditech Ltd. Financial Statement Overview

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.44B	1.43B	1.41B	1.25B	1.30B	962.08M
Gross Profit	680.70M	663.39M	691.60M	625.34M	609.47M	436.18M
EBITDA	253.71M	247.31M	374.31M	271.91M	287.20M	185.27M
Net Income	101.89M	92.39M	173.52M	-349.62M	-190.45M	99.37M
Balance Sheet
Total Assets	2.57B	2.57B	2.84B	2.72B	2.43B	2.24B
Cash, Cash Equivalents and Short-Term Investments	383.68M	518.99M	833.04M	814.16M	609.00M	307.50M
Total Debt	469.06M	552.24M	664.36M	756.00M	2.62B	1.74B
Total Liabilities	897.99M	978.12M	1.15B	1.23B	3.06B	2.19B
Stockholders Equity	1.66B	1.58B	1.68B	1.47B	-656.43M	25.63M
Cash Flow
Free Cash Flow	125.16M	26.57M	203.44M	186.41M	136.44M	128.19M
Operating Cash Flow	142.55M	107.78M	249.04M	234.42M	164.49M	130.00M
Investing Cash Flow	36.66M	18.55M	-167.65M	-136.04M	79.83M	-998.02M
Financing Cash Flow	-410.22M	-303.09M	-189.94M	3.08M	72.84M	856.36M

Gaush Meditech Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.64
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2407, the sentiment is Negative. The current price of 7.64 is above the 20-day moving average (MA) of 5.49, above the 50-day MA of 6.36, and below the 200-day MA of 7.72, indicating a bearish trend. The MACD of -0.25 indicates Negative momentum. The RSI at 43.00 is Neutral, neither overbought nor oversold. The STOCH value of 13.92 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2407.

Gaush Meditech Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1763	74 Outperform	HK$6.40B	18.20	8.41%	2.76%	13.59%	6.31%
2407	74 Outperform	HK$798.59M	5.97	6.29%	3.48%	6.63%	12.96%
1846	69 Neutral	HK$863.39M	5.69	6.49%	1.99%	-1.61%	-27.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
6622	47 Neutral	HK$1.67B	-7.14	-12.64%	―	-38.38%	-22.12%
2126	41 Neutral	HK$912.08M	-1.73	-59.45%	―	2.45%	2.58%
2216	41 Neutral	HK$724.37M	-4.03	-9.19%	―	-30.60%	28.61%

Gaush Meditech Ltd. Corporate Events